FIELD: medicine.
SUBSTANCE: set of inventions relates to methods for treating a malignant tumor. A method for treating a subject with a Trk-associated malignant tumor involves (a) administering one or more doses of the first Trk inhibitor to the subject over a period of time where the first Trk inhibitor is sulfate (S)- N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidine-1-yl)pyrazolo[1,5-a]pyrimidine-3-yl)-3-hydroxypyrrolidine-1-carboxamide; and (b) treatment after (a) involving a second Trk inhibitor of the subject where the second Trk inhibitor is (6R, 15R)-9-fluoro-15-methyl-2,11,16,20,21,24-hexaazapentacyclo[16.5.2.02,6.07,12.021,25]pentacose-1(24),7,9,11,18(25),19,22-hepten-17-on where the Trk-associated malignant tumor is resistant to the first Trk inhibitor. Disclosed are also other treatment options for a subject with a Trk-associated malignant tumor.
EFFECT: set of inventions enables treatment of Trk-associated malignant tumors.
64 cl, 17 dwg, 7 tbl, 4 ex
| Title |
Year |
Author |
Number |
| N-PYRROLIDINYL-UREA, N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS |
2013 |
- Allen Shelli
- Brandkhuber Barbara Dzh.
- Kerkher Timoti
- Kolakovski Gabriel R.
- Vinski Shennon L.
|
RU2677667C2 |
| LIQUID COMPOSITIONS (S)-N-(5-((R)-2-(2,5-DIFLUOROPHENYL)PYRROLIDINE-1-YL)PYRAZOLO[1,5-A]PYRIMIDINE-3-YL)-3-HYDROXYPYRROLIDINE-1-ARBOXAMIDE |
2017 |
- Rejnolds Mark
- Smit Stiven A.
|
RU2751767C2 |
| METHODS FOR TREATMENT OF CHILDHOOD CANCER DISEASES |
2017 |
- Koks Majkl
- Nanda Nisha
- Rejnolds Mark
- Smit Stiven A.
|
RU2751636C2 |
| 1-((3S,4R)-4-(3-FLUOROPHENYL)-1-(2-METHOXYETHYL)PYRROLIDIN-3-YL)-3-(4-METHYL-3-(2-METHYLPYRIMIDIN-5-YL)-1-PHENYL-1N-PYRAZOL-5-YL)UREA AS A TRKA KINASE INHIBITOR |
2015 |
- Allen Shelli
- Endryus Stiven U.
- Baer Brajan
- Krejn Zekeri
- Lyu Vejdun
- Uotson Deniel Dzhon
|
RU2719489C2 |
| PYRROLIDINYL UREA AND PYRROLIDINYL THIOUREA COMPOUNDS AS TRKA KINASE INHIBITORS |
2012 |
- Allen Shelli
- Endryus Stiven U.
- Blejk Dzhejms F.
- Kondroski Kevin R.
- Khaas Yuliya
- Khuan Lili
- Tszyan Yujtun
- Kerkher Timoti
- Kolakovski Gabriel R.
- Seo Dzeongbeob
|
RU2606131C2 |
| CRYSTALLINE FORM (S)-N-(5-((R)-2-(2,5-DIFLUOROPHENYL)-PYRROLIDIN-1-YL)-PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-3-HYDROXYPYRROLIDINE-1-CARBOXAMIDE HYDROSULPHATE |
2015 |
- Errigo Alisha B.
- Dzhuengst Derrik
- Shakh Khalid
|
RU2723990C2 |
| IDENTIFICATION OF LKB1 MUTATION AS PROGNOSTIC BIOMARKER OF SENSITIVITY TO TOR-KINASE INHIBITORS |
2011 |
- Sankar Sabita
- Chopra Radzhesh
- Sjuj Vehjmin
- Nin Jujkhun
- Sju Shujchan'
|
RU2565034C2 |
| SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TROPOMYOSIN-RELATED KINASE INHIBITORS |
2009 |
- Khaas Julija
- Ehndrjus Stiven U.
- Tszjan Jujtun
- Chzhan Gan'
|
RU2523544C2 |
| MDM2 PROTEIN DESTRUCTORS |
2017 |
- Wang, Shaomeng
- Li, Yangbing
- Yang, Jiuling
- Aguilar, Angelo
- Zhou, Bing
- Hu, Jiantao
- Xu, Fuming
- Rej, Rohan
- Han, Xin
|
RU2743432C2 |
| SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS INHIBITORS OF TRK KINASE |
2014 |
- Khaas Yuliya
- Endryus Stiven U.
- Tszyan Yujtun
- Chzhan Gan
|
RU2666367C2 |
